Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
J Microsc ; 231(2): 234-46, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18778421

ABSTRACT

The cell cycle is regulated by the cyclin-dependent kinase (CDK), and CDK inhibitors can bind to CDKs and inhibit their activities. This review examines plant CDK inhibitors, with particular emphasis on their molecular and cellular functions, regulation and cellular localization. In plants, a family of ICK/KRP CDK inhibitors represented by ICK1 is known and another type of CDK inhibitor represented by the SIMESE (SIM) has recently been reported. Considerable understanding has been gained with the ICK/KRP CDK inhibitors. These plant CDK inhibitors share only limited sequence similarity in the C-terminal region with the KIP/CIP family of mammalian CDK inhibitors. The ICK/KRP CDK inhibitors thus provide good tools to understand the basic machinery as well as the unique aspects of the plant cell cycle. The ICK/KRP CDK inhibitors interact with D-type cyclins or A-type CDKs or both. Several functional regions and motifs have been identified in ICK1 for CDK inhibition, nuclear localization and protein instability. Clear evidence shows that ICK/KRP proteins are important for the cell cycle and endoreduplication. Preliminary evidence suggests that they may also be involved in cell differentiation and cell death. Results so far show that plant CDK inhibitors are exclusively localized in the nucleus. The molecular sequences regulating the localization and functional significance will be discussed.


Subject(s)
Cell Cycle , Cyclin-Dependent Kinase Inhibitor Proteins/analysis , Cyclin-Dependent Kinase Inhibitor Proteins/physiology , Plant Physiological Phenomena , Plants/chemistry
2.
Planta ; 213(6): 888-97, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11722125

ABSTRACT

In opium poppy (Papaver somniferum L.), (S)-reticuline is the last common intermediate in sanguinarine and morphine biosynthesis. Sanguinarine accumulates in the vacuole of cultured opium poppy cells in response to treatment with fungal elicitors. The first committed step in sanguinarine biosynthesis is catalyzed by the berberine bridge enzyme (BBE), which converts (S)-reticuline to (S)-scoulerine. An N-terminal signal peptide and novel vacuolar sorting determinant were identified and characterized in BBE. In vitro translation of BBE mRNA in the presence of canine pancreatic microsomes produced a glycosylated, proteolysis-resistant protein, confirming the existence of a signal peptide. Transcripts encoding a BBE N-terminal deletion series fused to beta-glucuronidase or green fluorescent protein (GFP) were also translated in the presence of canine microsomes, and introduced into cultured opium poppy cells via microprojectile bombardment. The signal peptide was restricted to the first 25 amino acids and shown to initially target BBE to the endoplasmic reticulum. Fusion of 50 N-terminal residues from BBE to GFP resulted in the localization of the reporter to the vacuole. GFP was also sorted to the vacuole when fused to a heterologous N-terminal signal peptide followed by BBE amino acids 26-50. The BBE vacuolar sorting determinant was further localized between residues 26 and 41 by deletion analysis. The final subcellular destination of BBE is consistent with the vacuolar sequestration of sanguinarine. However, the vacuolar pH is below the functional range for BBE, suggesting that the enzyme is active only prior to its entry into the vacuole.


Subject(s)
Alkaloids/biosynthesis , Oxidoreductases, N-Demethylating/metabolism , Papaver/metabolism , Vacuoles/metabolism , Amino Acid Sequence , Animals , Benzophenanthridines , Cells, Cultured , Endoplasmic Reticulum/metabolism , Gene Expression Regulation, Plant , Glucuronidase/genetics , Glucuronidase/metabolism , Glycosylation , Green Fluorescent Proteins , Isoquinolines , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Microscopy, Fluorescence , Molecular Sequence Data , Oxidoreductases, N-Demethylating/genetics , Papaver/genetics , Protein Biosynthesis , Protein Sorting Signals/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Sequence Homology, Amino Acid , Transcription, Genetic
3.
Ann N Y Acad Sci ; 947: 214-22; discussion 222-3, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11795269

ABSTRACT

Oxidized LDL (OxLDL) competes with oxidatively damaged and apoptotic cells for binding to mouse peritoneal macrophages, implying the presence of one or more common domains. However, the nature of the ligands involved has not been determined. Studies in this laboratory over the last several years provide evidence that oxidized phospholipids, present in OxLDL and also in the membrane of apoptotic cells, represent one such ligand. These oxidized phospholipids, either in the lipid phase of OxLDL or becoming attached covalently to apoprotein B during LDL oxidation, have been shown to play a major role in the binding of OxLDL to CD36 and to SR-B1 expressed in transfected cells. The lipid and protein moieties compete with each other to some extent, indicating that they are binding to at least one common site. A monoclonal antibody selected because of its reactivity with OxLDL proved to be an antibody against oxidized phospholipids (but not native phospholipids). This antibody (EO6) blocked the uptake of OxLDL by CD36 and by SR-B1 in transfected cells by as much as 80%; it also inhibited macrophage phagocytosis of apoptotic cells by about 40%. Thus, the persistence of receptors for OxLDL during evolution is probably accounted for by their role in recognition of ligands on the surfaces of oxidatively damaged or apoptotic cells. This has important implications in biology generally and specifically in atherogenesis, because apoptosis is a prominent feature of late lesions.


Subject(s)
Arteriosclerosis/physiopathology , Lipoproteins, LDL/physiology , Membrane Proteins , Receptors, Immunologic/physiology , Receptors, Lipoprotein , Animals , Apoptosis , Arteriosclerosis/etiology , Arteriosclerosis/pathology , CD36 Antigens , Humans , Lipoproteins, LDL/blood , Receptors, Scavenger , Scavenger Receptors, Class B
4.
Proc Natl Acad Sci U S A ; 96(11): 6347-52, 1999 May 25.
Article in English | MEDLINE | ID: mdl-10339590

ABSTRACT

It has been shown previously that the binding of oxidized low-density lipoprotein (OxLDL) to resident mouse peritoneal macrophages can be inhibited (up to 70%) by the apoprotein B (apoB) isolated from OxLDL, suggesting that macrophage recognition of OxLDL is primarily dependent on its modified protein moiety. However, recent experiments have demonstrated that the lipids isolated from OxLDL and reconstituted into a microemulsion can also strongly inhibit uptake of OxLDL (up to 80%). The present studies show that lipid microemulsions prepared from OxLDL bind to thioglycollate-elicited macrophages at 4 degrees C in a saturable fashion and inhibit the binding of intact OxLDL and also of the apoB from OxLDL. Reciprocally, the binding of the OxLDL-lipid microemulsions was strongly inhibited by intact OxLDL. A conjugate of synthetic 1-palmitoyl 2(5-oxovaleroyl) phosphatidylcholine (an oxidation product of 1-palmitoyl 2-arachidonoyl phosphatidylcholine) with serum albumin, shown previously to inhibit macrophage binding of intact OxLDL, also inhibited the binding of both the apoprotein and the lipid microemulsions prepared from OxLDL. Finally, a monoclonal antibody against oxidized phospholipids, one that inhibits binding of intact OxLDL to macrophages, also inhibited the binding of both the resolubilized apoB and the lipid microemulsions prepared from OxLDL. These studies support the conclusions that: (i) at least some of the macrophage receptors for oxidized LDL can recognize both the lipid and the protein moieties; and (ii) oxidized phospholipids, in the lipid phase of the lipoprotein and/or covalently linked to the apoB of OxLDL, likely play a role in that recognition.


Subject(s)
Lipoproteins, LDL/metabolism , Macrophages, Peritoneal/physiology , Phosphatidylcholines/pharmacokinetics , Receptors, LDL/physiology , Animals , Apolipoproteins B/metabolism , Apoptosis , Cells, Cultured , Emulsions , Female , Humans , Kinetics , Lipoproteins, LDL/blood , Lipoproteins, LDL/isolation & purification , Liposomes , Macrophages, Peritoneal/cytology , Mice , Phosphatidylcholines/chemical synthesis , Receptors, Oxidized LDL , Scavenger Receptors, Class E , Serum Albumin, Bovine/pharmacokinetics , Substrate Specificity
5.
J Clin Invest ; 103(1): 117-28, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9884341

ABSTRACT

We recently cloned monoclonal IgM autoantibodies which bind to epitopes of oxidized low-density lipoprotein (OxLDL) from apoE-deficient mice (EO- autoantibodies). We now demonstrate that those EO- autoantibodies that were originally selected for binding to copper-oxidized low-density lipoproteins (CuOx-LDL), also bound both to the oxidized protein and to the oxidized lipid moieties of CuOx-LDL. The same EO- autoantibodies showed specific binding to products of oxidized 1-palmitoyl-2-arachidonoyl-phosphatidylcholine (OxPAPC) and to the specific oxidized phospholipid, 1-palmitoyl-2-(5-oxovaleroyl)-phosphatidyl-choline (POVPC), whereas oxidation of fatty acids (linoleic or arachidonic acid) or cholesteryl esters (cholesteryl-oleate or cholesteryl-linoleate) did not yield any binding activity. Those EO- autoantibodies that bound to oxidized phospholipids (e.g., EO6) inhibited the binding and degradation of CuOx-LDL by mouse peritoneal macrophages up to 91%, whereas other IgM EO- autoantibodies, selected for binding to malondialdehyde (MDA)-LDL, had no influence on binding of either CuOx-LDL or MDA-LDL by macrophages. F(ab')2 fragments of EO6 were equally effective as the intact EO6 in preventing the binding of CuOx-LDL by macrophages. The molar ratios of IgM to LDL needed to maximally inhibit the binding varied from approximately 8 to 25 with different CuOx-LDL preparations. Finally, a POVPC-bovine serum albumin (BSA) adduct also inhibited CuOx-LDL uptake by macrophages. These data suggest that oxidized phospholipid epitopes, present either as lipids or as lipid-protein adducts, represent one class of ligands involved in the recognition of OxLDL by macrophages, and that apoE-deficient mice have IgM autoantibodies that can bind to these neoepitopes and inhibit OxLDL uptake.


Subject(s)
Antibodies, Monoclonal/immunology , Lipoproteins, LDL/immunology , Macrophages, Peritoneal/metabolism , Animals , Antibodies, Monoclonal/metabolism , Apolipoproteins E/deficiency , Apolipoproteins E/genetics , Autoantibodies/immunology , Autoantibodies/metabolism , Copper/pharmacology , Emulsions/metabolism , Epitopes/immunology , Immunoglobulin Fab Fragments/immunology , Immunoglobulin Fab Fragments/metabolism , Lipid Peroxides/immunology , Lipoproteins, LDL/metabolism , Liposomes/immunology , Liposomes/metabolism , Mice , Phospholipids/immunology , Protein Binding
6.
J Lipid Res ; 39(5): 1079-90, 1998 May.
Article in English | MEDLINE | ID: mdl-9610776

ABSTRACT

Probucol is a powerful inhibitor of atherosclerosis in a number of animal models. However, it is unknown whether this is due to the strong antioxidant protection of low density lipoprotein (LDL), to antioxidant effects in the artery wall, or to cellular effects not shared by other antioxidants. To investigate whether murine models are suitable to study the antiatherogenic mechanisms of probucol, three experiments following different protocols were carried out in 135 male and female LDL receptor-deficient (LDLR-/-) mice. Treatment groups received a high (0.5%) or low (0.025%) dose of probucol, or low-dose probucol plus a high dose (0.1%) of vitamin E for periods ranging from 6 to 26 weeks. In all experiments, probucol strongly protected LDL against ex vivo oxidation (lag times exceeding 1400 min in 0.5% probucol-treated mice). Treatment with 0.5% probucol significantly lowered both HDL-cholesterol and plasma apolipoprotein (apo)A-I concentrations. In all three experiments, treatment with 0.5% probucol consistently increased the size of lesions in the aortic origin, from 1.3-fold (n.s.) to 2.9-fold (P < 0.05) in female mice and from 3.6- to 3.7-fold in males (P < 0.001). Even treatment with 0.025% probucol increased atherosclerosis 1.6-fold in male mice (P < 0.01). Addition of the high dose of vitamin E did not attenuate the pro-atherogenic effect of 0.025% probucol. In conclusion, probucol not only failed to decrease but actively increased atherogenesis in LDLR-/- mice in a dose-dependent manner, even though it provided a very strong antioxidant protection of LDL. This suggests that the reduction of atherosclerosis observed in other animal models is due to intracellular effects of probucol not found in mice, to differences in the metabolism of probucol, and/or to an overriding atherogenic effect of the decrease in HDL in murine models.


Subject(s)
Anticholesteremic Agents/pharmacology , Arteriosclerosis/blood , Lipoproteins, LDL/blood , Probucol/pharmacology , Receptors, LDL/physiology , Animals , Anticholesteremic Agents/blood , Cholesterol, Dietary/blood , Cholesterol, Dietary/pharmacology , Female , Lipoproteins, HDL/blood , Male , Mice , Mice, Inbred C57BL , Probucol/blood , Receptors, LDL/blood , Vitamin E/blood , Vitamin E/pharmacology
7.
Proc Natl Acad Sci U S A ; 95(4): 1806-11, 1998 Feb 17.
Article in English | MEDLINE | ID: mdl-9465098

ABSTRACT

The binding of oxidatively damaged red blood cells (OxRBCs) to resident mouse peritoneal macrophages correlates with an increase in phosphatidylserine on the external leaflet of the plasma membrane. Liposomes rich in phosphatidylserine can inhibit this binding and also the binding of certain apoptotic cells. We have shown previously that oxidized low density lipoproteins (OxLDL) also can inhibit the binding of OxRBCs to resident mouse peritoneal macrophages. The present studies show that microemulsions prepared from the lipids extracted from OxLDL are very effective in inhibiting the binding of OxRBCs and also, to a lesser extent, of apoptotic thymocytes to macrophages. OxRBC binding was also inhibited by cholesterol phospholipid liposomes containing oxidized 1-stearoyl-2-linoleoyl-phosphatidylcholine. The binding and uptake of 125I-labeled OxLDL were also strongly inhibited by microemulsions of the lipids extracted from OxLDL and by cholesterol phospholipid liposomes containing oxidized 1-palmitoyl-2-arachidonoyl-phosphatidylcholine. Earlier studies have shown that the delipidated protein moiety of OxLDL can competitively inhibit macrophage binding of intact OxLDL, implicating the protein moiety as an effective receptor-binding domain of OxLDL with respect to some macrophage scavenger receptors. The present studies suggest that the lipid moiety of OxLDL may also play a role.


Subject(s)
Lipid Metabolism , Lipoproteins, LDL/metabolism , Macrophages, Peritoneal/metabolism , Membrane Proteins , Receptors, Immunologic/metabolism , Receptors, Lipoprotein , Animals , Apolipoproteins B/metabolism , Emulsions , Humans , Liposomes , Mice , Phagocytosis , Receptors, Scavenger , Scavenger Receptors, Class B , Structure-Activity Relationship
8.
Alcohol Clin Exp Res ; 21(4): 602-5, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9194911

ABSTRACT

Fatty acid ethyl esters (FAEEs) are nonoxidative products of ethanol metabolism and have been implicated as mediators of ethanol-induced organ damage. Previous studies have demonstrated that FAEEs bind to lipoproteins and albumin in human plasma after ethanol ingestion. Analysis of human serum with varying blood ethanol levels and endogenously formed FAEEs revealed a positive correlation between serum FAEE concentration and the percentage of FAEEs associated with lipoproteins, predominantly very low density and low density lipoprotein. Similar results were obtained when increasing amounts of FAEEs were added to serum with zero blood ethanol. Additional studies indicated that free fatty acids and FAEEs do not compete for binding to albumin or lipoproteins. Data support the conclusion that the distribution of FAEEs among their carriers in the serum is dependent on serum FAEE concentration.


Subject(s)
Acyltransferases/physiology , Alcoholic Intoxication/blood , Alcoholism/blood , Ethanol/pharmacokinetics , Fatty Acids/blood , Lipoproteins/blood , Binding, Competitive/physiology , Esterification , Humans , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Lipoproteins, VLDL/blood , Oleic Acids/blood , Palmitic Acids/blood , Reference Values , Serum Albumin/metabolism
9.
J Lipid Res ; 38(12): 2455-64, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9458269

ABSTRACT

Oxidation of LDL plays all important role in atherogenesis. The lag-time in the formation of conjugated dienes provides a sensitive measure of the resistance of plasma LDL to oxidation and is widely assumed to be an indicator of atherogenic risk. To test this assumption, we investigated whether different antioxidants yielding similar lag-times result in similar reduction of atherosclerosis. A 6-months intervention study was carried out in three groups of 10 LDL receptor-deficient rabbits each. Because previous studies indicated that antioxidants that reduce atherosclerosis resulted in very long lag-times, the first group was treated with an antioxidant combination containing 1,000 IU vitamin E, 0.05% probucol analogue (BM15.0639), and 0.025% probucol. The lag-times achieved throughout the intervention period by this combination (952 +/- 39 min) were matched in a second group (829 +/- 46 min) treated with a variable dose of probucol (0.0575-0.11%, average 0.091%). A third, untreated group served as a control. Plasma cholesterol levels of all groups were matched. Even though both treatments yielded similar antioxidant protection of plasma LDL, 0.091% probucol reduced aortic atherosclerosis by 51.7% compared to the untreated group (P < 0.005), whereas the antioxidant combination failed to reduce lesion formation. Thus, the lag-time is clearly not correlated with the antiatherogenic efficacy of different antioxidants. However, a weak correlation was found within the group treated with probucol only. Our results suggest that the degree of antioxidant protection of plasma LDL may not be a good indicator of the atherogenic risk, in general, and that probucol reduces atherogenesis by mechanisms not shared by all antioxidants.


Subject(s)
Antioxidants/pharmacology , Lipid Peroxidation/drug effects , Lipoproteins, LDL/metabolism , Animals , Arteriosclerosis/drug therapy , Arteriosclerosis/metabolism , Body Weight , Cholesterol/blood , Lipoproteins, LDL/adverse effects , Lipoproteins, LDL/blood , Phenols/pharmacology , Probucol/pharmacology , Rabbits , Receptors, LDL/deficiency , Receptors, LDL/genetics , Statistics as Topic , Time Factors , Triglycerides/analysis , Triglycerides/blood , Vitamin E/pharmacology
10.
J Lipid Res ; 37(7): 1449-58, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8827517

ABSTRACT

Fatty acid ethyl esters (FAEE), esterification products of ethanol and fatty acids, have been implicated as mediators of ethanol-induced organ damage. After ethanol ingestion in humans, FAEE circulate in blood, bound to lipoproteins and albumin. We have analyzed the binding of ethyl (1-13C, 99%) oleate (EO) to small unilamellar phospholipid vesicles (SUV), human low density lipoprotein (LDL), and bovine serum albumin (BSA) by 13C-NMR spectroscopy. Binding of < or = 25 mol% EO to SUV yielded a single EO carbonyl peak (172.6-172.9 ppm) downfield from that of EO oil (171.9 ppm). Thus, the carbonyl forms hydrogen bonds with water in the SUV aqueous interface. At 30 mol% EO in SUV, a second EO carbonyl peak appeared, indicating a limit in FAEE solubility in SUV. Addition of EO to isolated human LDL yielded a peak at 171.9 ppm, suggesting that the EO exists in an unhydrated environment, most likely the core of the lipoprotein. This binding was also observed using high levels of EO added to human serum. The addition of EO dissolved in ethanol or as an oil to a solution of BSA yielded no visible EO peak, whereas addition of (1-13C, 99%) oleic acid resulted in several narrow peaks, demonstrating a much greater affinity of BSA for oleic acid than for EO. Bidirectional transfer of EO between LDL and SUV was observed and was 85% complete within 30 min. There was no measurable transfer of EO from LDL or SUV to albumin. The weak binding of EO to albumin will result in increased transport of EO by lipoproteins as plasma levels of EO increase.


Subject(s)
Lipoproteins, LDL/chemistry , Oleic Acids/chemistry , Phospholipids/chemistry , Serum Albumin/chemistry , Carbon Isotopes , Lipid Bilayers/chemistry , Magnetic Resonance Spectroscopy , Protein Binding
11.
J Chromatogr B Biomed Appl ; 675(2): 189-96, 1996 Jan 26.
Article in English | MEDLINE | ID: mdl-8852705

ABSTRACT

We have developed a two-step method to purify fatty acid ethyl esters (FAEE) using solid-phase extraction (SPE), with a recovery of 70 +/- 3% (mean +/- S.E.M.) as assessed using ethyl oleate as a recovery marker from a standard lipid mixture in hexane. The first step of the SPE procedure involves application of a lipid mixture to an aminopropyl-silica column with simultaneous elution of FAEE and cholesteryl esters from the column with hexane. Gas chromatographic analysis of FAEE without interference from cholesteryl esters may be performed using the eluate from the aminopropyl-silica column, thus eliminating the need for an octadecylsilyl (ODS) column in this case. The FAEE can then be separated from the cholesteryl esters, if necessary, by chromatography on an ODS column and elution with isopropanol-water (5:1, v/v). Both the aminopropyl-silica and ODS columns were found to be effective for up to four uses. To permit isolation of specific FAEE species following isolation of total FAEE by the two-step SPE method, we have also developed a purification scheme for individual FAEE by high-performance liquid chromatography (HPLC). Thus, this simple method allows for reproducible isolation of total FAEE by SPE and isolation of individual FAEE species by HPLC.


Subject(s)
Fatty Acids/chemistry , Chromatography, High Pressure Liquid , Chromatography, Thin Layer , Esters/blood , Esters/chemistry , Esters/isolation & purification , Gas Chromatography-Mass Spectrometry , Humans , Radiometry
12.
Alcohol Clin Exp Res ; 19(5): 1265-70, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8561300

ABSTRACT

Fatty acid ethyl esters (FAEEs), esterification products of ethanol and fatty acids, have been found selectively in the organs damaged by ethanol abuse, and on that basis have been implicated as contributors to ethanol-induced organ damage. To directly assess the cytotoxic potential of FAEEs with intact cells in a physiological system, solubility must be achieved for these highly nonpolar lipids in aqueous medium. After ethanol ingestion, FAEEs can be found within low-density lipoproteins (LDLs). Therefore, to achieve solubility with FAEEs bound to a naturally occurring lipid carrier, we developed a method for FAEE solubilization and delivery to cells in culture. We synthesized radiolabeled FAEEs and incorporated them into human LDL particles that bind to LDL receptors and deliver FAEEs to intact cells. Ethyl palmitate and ethyl oleate were incorporated into LDLs yielding molar ratios of FAEEs to LDLs of 2,153 +/- 249 and 4,208 +/- 403, respectively. LDL reconstituted with FAEE had the same electrophoretic mobility on agarose gel electrophoresis as native LDL, indicating that the reconstituted LDL (rLDL) was not oxidatively modified. Quantitative analysis of the solubilization of FAEEs in aqueous medium was investigated by adding FAEEs to tissue culture medium either directly or reconstituted in LDL at a concentration of 27 microM. The percentage of FAEE quantitated was 40.0 +/- 2.5% and 89.3 +/- 0.6% for FAEEs added directly and in rLDLs, respectively. After sterile filtration of these two media, the percentage of FAEE that remained was 11.8 +/- 1.3% (direct addition) and 74.9 +/- 1.3% (addition within rLDL), further demonstrating that the LDL particle did solubilize the FAEE.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Ethanol/pharmacokinetics , Lipoproteins, LDL/blood , Oleic Acids/pharmacokinetics , Palmitic Acids/pharmacokinetics , Carcinoma, Hepatocellular , Cell Line , Ethanol/toxicity , Humans , Liver Neoplasms , Oleic Acids/toxicity , Palmitic Acids/toxicity , Receptors, LDL/metabolism , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism
13.
J Lipid Res ; 35(3): 428-37, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8014578

ABSTRACT

The aim of the study was to determine whether fatty acid ethyl esters, nonoxidative products of ethanol metabolism selectively present in organs damaged by ethanol abuse, are detectable in the serum after ethanol ingestion. Serum samples of hospital emergency room patients with positive (n = 32) and negative (n = 5) blood ethanol levels were assayed for fatty acid ethyl esters. In a separate study, five healthy subjects received an ethanol dose based on body weight mixed with fruit juice in a 1:2 ratio and administered by measured ingestion. Fatty acid ethyl esters were found in the serum of hospital emergency room patients with positive blood ethanol levels. The concentration of fatty acid ethyl esters in these patients correlated with the concentration of blood ethanol (r = 0.57; 95% confidence interval 0.28 to 0.77; P = 0.0002). In the controlled ethanol ingestion study with five healthy subjects, it was also determined that the serum fatty acid ethyl ester concentration began to decrease within 2 h of the time ethanol ingestion had been stopped. The fatty acid ethyl esters in the serum were bound to lipoprotein and albumin, and there was a higher percentage of saturated fatty acids in the FAEE pool than in the serum free fatty acid and triglyceride pools. These studies indicate that fatty acid ethyl esters, which have been implicated as mediators of ethanol-induced organ toxicity, are present in serum after ethanol ingestion.


Subject(s)
Esters/blood , Ethanol/metabolism , Fatty Acids/blood , Ethanol/administration & dosage , Ethanol/blood , Fatty Acids, Nonesterified/blood , Gas Chromatography-Mass Spectrometry , Humans , Kinetics , Lipoproteins/blood , Protein Binding , Serum Albumin/metabolism
14.
Med Inform (Lond) ; 4(2): 69-78, 1979.
Article in English | MEDLINE | ID: mdl-491794

ABSTRACT

This paper relates issues encountered in extending a centralized computer-based nurse scheduling system to support daily staffing decisions in a hospital environment. When calculating the daily staffing needs on each nursing unit, the conceptually simple interactive staffing system incurred considerable costs in categorizing patients according to level of care required. Two years of historical data collected daily in a 568 bed St. Louis hospital were used to test the sensitivity of relative staffing requirements to daily fluctuations in patient-care distributions. A periodic sampling plan appears adequate for updating distributions which can then be applied to current census in estimating daily staffing needs. Recommendations for implementing such a system are offered.


Subject(s)
Computers , Nursing Staff, Hospital , Personnel Management , Personnel Staffing and Scheduling , Humans , Nursing Care/classification
SELECTION OF CITATIONS
SEARCH DETAIL
...